During Round 4 of Immunotherapy, she was able to get nearly 100% of the cancer-fighting antibody drug, Unituxin, and about 50% of the immune system booster infusion, IL-2. Unfortunately, the combination of both drugs together was just too much on her body for all 4 days, so her team (including us) decided it was best to continue with just the antibody (Unituxin), and discontinue the IL-2, which is considered a lesser priority drug for this round. This adjustment/discontinuation is not uncommon this late into immunotherapy; their bodies are weak and worn from 14 months of toxic treatment. It was a hard decision, and not taken lightly, but luckily, her blood counts remained ok throughout the stay, and we were pleased with their explanation and quick reaction to adjust this round's protocol.
It's been a stressful, draining and exhausting couple of weeks, and we are all looking forward to spending quality family time together - under one roof - over the next few weeks!
THANK YOU for all the continued support and prayers!
The Lantz Family